Immunotherapy for Glioblastoma: Playing Chess, Not Checkers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29691293.
- Also identified by DOI 10.1158/1078-0432.CCR-18-0491.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with glioblastoma (GBM) exhibit a complex state of immune dysfunction involving multiple mechanisms of local, regional, and systemic immunosuppression and tolerance. These pathways are now being identified and their relative contributions explored. Delineating how these pathways are interrelated is paramount to effectively implementing immunotherapy for GBM. <i>Clin Cancer Res; 24(17); 4059-61. ©2018 AACR</i><i>See related articles by Woroniecka et al., p. 4175 and Mohme et al., p. 4187</i>.
Medical subject headings
- Glioblastoma